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Abstract
Background: Lung cancer is the leading cause of cancer deaths worldwide. New diagnostics are needed to detect early
stage lung cancer because it may be cured with surgery. However, most cases are diagnosed too late for curative surgery.
Here we present a comprehensive clinical biomarker study of lung cancer and the first large-scale clinical application of a
new aptamer-based proteomic technology to discover blood protein biomarkers in disease.
Methodology/Principal Findings: We conducted a multi-center case-control study in archived serum samples from 1,326
subjects from four independent studies of non-small cell lung cancer (NSCLC) in long-term tobacco-exposed populations.
Sera were collected and processed under uniform protocols. Case sera were collected from 291 patients within 8 weeks of
the first biopsy-proven lung cancer and prior to tumor removal by surgery. Control sera were collected from 1,035
asymptomatic study participants with $10 pack-years of cigarette smoking. We measured 813 proteins in each sample with
a new aptamer-based proteomic technology, identified 44 candidate biomarkers, and developed a 12-protein panel
(cadherin-1, CD30 ligand, endostatin, HSP90a, LRIG3, MIP-4, pleiotrophin, PRKCI, RGM-C, SCF-sR, sL-selectin, and YES) that
discriminates NSCLC from controls with 91% sensitivity and 84% specificity in cross-validated training and 89% sensitivity
and 83% specificity in a separate verification set, with similar performance for early and late stage NSCLC.
Conclusions/Significance: This study is a significant advance in clinical proteomics in an area of high unmet clinical need.
Our analysis exceeds the breadth and dynamic range of proteome interrogated of previously published clinical studies of
broad serum proteome profiling platforms including mass spectrometry, antibody arrays, and autoantibody arrays. The
sensitivity and specificity of our 12-biomarker panel improves upon published protein and gene expression panels. Separate
verification of classifier performance provides evidence against over-fitting and is encouraging for the next development
phase, independent validation. This careful study provides a solid foundation to develop tests sorely needed to identify
early stage lung cancer.
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Lung cancer is the leading cause of cancer deaths, because
,84% of cases are diagnosed at an advanced stage [1–3].
Worldwide in 2008, ,1.5 million people were diagnosed and
,1.3 million died [4] – a survival rate unchanged since 1960.
However, patients diagnosed at an early stage and have surgery
experience an 86% overall 5-year survival [2,3]. New diagnostics
are therefore needed to identify early stage lung cancer.
Over the past decade the clinical utility of low-dose CT has
been evaluated [5–8] with the hope that high-resolution imaging
can help detect lung cancer earlier and improve patient outcomes,
much as screening has done for breast and colorectal cancers [9].
Definitive conclusions about CT screening and lung cancer
mortality await results from randomized trials in the US [8] and
Europe [10–13]. CT can detect small, early-stage lung tumors, but
distinguishing rare cancers from common benign conditions is
difficult and has led to unnecessary procedures, radiation
exposure, anxiety, and cost [6,14–16]. We (J.M.S., J.L.W., and
colleagues) recently reported such conclusions for the Pittsburgh
Lung Screening Study (PLuSS), the largest single-institution CT
screening study reported to date [5].
Other types of biomarkers have also been sought [17]. Proteins
are attractive because they are an immediate measure of
phenotype, in contrast to DNA which provides genotype, largely
a measure of disease risk [18]. Single protein biomarkers are the
foundation of molecular diagnostics in the clinic today. It is widely
thought that multiple biomarkers could improve the sensitivity and
specificity of diagnostic tests, and that complex diseases like cancer
change the concentrations of multiple proteins [19]. However,
discovering multiple protein biomarkers by measuring many
proteins simultaneously (proteomics) in complex samples like
blood has proven difficult for reasons of coverage, precision,
throughput, preanalytical variability, and cost [20].
To enable biomarker discovery, we developed a new proteomic
technology that is based on a new generation of aptamer protein
binding reagents and has potentially broad application [18]. The
current assay measures 813 diverse human proteins in just 15 mL
of blood with low limits of detection (1 pM average and as low as
100 fM), 7 logs of overall dynamic range, and high reproducibility
(5% median coefficient of variation) [18]. Here we present the first
large scale clinical application of our proteomics technology to
discover blood protein biomarkers in a large multi-center case-
control study conducted in archived samples from 1,326 subjects
from four independent studies of non-small cell lung cancer
(NSCLC) in long-term tobacco-exposed populations.
Materials and Methods
Ethics Statement
All samples were collected from study participants after
obtaining written informed consent under clinical research
protocols approved by the following institutional review boards:
The University of Pittsburgh Institutional Review Board (Pitt);
The New York University School of Medicine Institutional
Review Board (NYU); The Roswell Park Cancer Institute
Institutional Review Board (RP); and The Cape Cod Healthcare
Institutional Review Board (BS).
Study Design
The objectives of this study were to discover biomarkers that
discriminate NSCLC from smokers with $10 years of cigarette
smoking history, to train and cross-validate a multi-biomarker
classifier of NSCLC to meet pre-specified performance criteria,
and to verify the performance of this classifier with a separate set of
blinded samples. The overall design of the study is shown in
Figure 1. We designed and executed this study to current rigorous
standards for biomarker clinical studies [21–23] with the goals of
maximize biomarker robustness, validity, and reliability at the
discovery phase, and minimizing potential effects of preanalytical
variability. The study was a discovery-phase, case-control design.
Critical study design features include the following. The clinical
question and study design were pre-specified prior to identifying
and acquiring samples. Samples were acquired from four
independent study sites in order to control for potential
preanalytical variability. Strict standard operating procedures
were followed to ensure sample and data anonymity and blinding
at all times (see below). A verification sample set consisting of 25%
of all samples in the study was randomly selected and the
identification of this set was blinded. The statistical analysis plan
was pre-specified and included minimally acceptable performance
criteria for sensitivity and specificity.
Sample Cohort
The sample cohort comprised 1,326 serum samples obtained from
four independent biorepositories: New York University (NYU) [24];
Roswell Park Cancer Institute (RPCI) [25]; The University of
Pittsburgh (PITT) [5]; and a commercial biorepository (BioServe (BS))
(Table 1). All samples were collected from study participants after
obtaining informed consent under institutionally approved clinical
research protocols asdescribed [5,24,25].Both case and control serum
samples were collected from four study centers. The clinical
characteristics of the study cohort for the training and verification
Figure 1. Study Flow for Algorithm Training and Verification.
doi:10.1371/journal.pone.0015003.g001
Table 1. Sample cohort by independent study site.
Site
Cases
(n=291)
Nodule
Controls
(n=565)
Smoker
Controls
(n=470) Total/Site
BS 43 0 63 106
RPCI 72 66 110 248
NYU 88 238 172 498
PITT 88 261 125 474
doi:10.1371/journal.pone.0015003.t001
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is shown in Table 3. The sample cohort included patients diagnosed
with pathologic or clinical stage I-III NSCLC and a high-risk control
population with a history of long-term tobacco use, including active
and ex-smokers with $10 pack-years of cigarette smoking. The
control populations were selected randomly within each study to
represent the patient population at risk for lung cancer that would be
candidates for CT screening, with a ratio of case:control of 1:3.5.
Blood samples for cases were collected from patients within eight
weeks of the first biopsy-proven lung cancer diagnosis and prior to
removal of the tumor by a surgical procedure. All cases used in this
study were confirmed as primary lung cancer by pathology review.
NSCLC staging was assigned by pathological staging for 240 subjects
and clinical staging for 51 subjects. Benign nodule controls have at
least one year of follow-up data and non-malignant diagnosis. Smoker
controls were asymptomatic study participants with $10 pack-years of
cigarette smoking. Smoker controls from NYU and Pitt were nodule
free by CT; nodule status is unknown for the smoker controls from RP
and BS.Demographicdata wascollectedbyself-reportquestionnaires.
Additional data for cases was acquired through clinical chart review.
Pulmonary function testing was assessed by spirometry for a subset of
the study participants.
Serum Collection, Processing, Storage, and Shipment
All serum specimens were collected following uniform protocols
recommended by the National Cancer Institute’s Early Detection
Research Network [22]. Three of the centers (NYU, PITT and
RPMC) collected serum in red top Vacutainer tubes (Becton
Dickinson, Raritan, NJ) and one center (BS) collected serum in
tiger top SST Vacutainer tubes (Becton Dickinson). All samples
were allowed to clot and serum was recovered by centrifugation
within 2–8 hours of collection and stored at 280uC. HIPAA
compliant, de-identified samples were shipped frozen on dry ice to
SomaLogic from the study centers and stored at -80uC. Samples
were thawed once for aliquoting prior to proteomic analysis.
Sample Blinding
In order to prevent potential bias, this study followed a strict
standard operating procedure for sample de-identification and
blinding, such that all physical samples and data records were
identified exclusively by a unique, unidentifiable barcode number
and the key was stored in a secure database accessible only to
designated responsible administrators. All sample aliquots run in
this study were stored in identical tubes identified only by assigned
barcode. The sample blinding code was broken only according to
the pre-specified analysis plan for the purposes of classifier training
with the training set and classifier verification with the verification
set. For the verification sample set, a unique blinding key was
generated and provided exclusively to a third party reader (K.C.),
unaffiliated with the study centers or SomaLogic, to score and
report the final verification results.
Proteomic Analysis
Serum samples were analyzed on our proteomic discovery
platform as described in Gold et al [5]. Briefly, this technology uses
Table 2. Clinical characteristics of NSCLC case and control sets for training and verification.
Training Set (n=985) Verification Set (n=341)
Cases Controls p-value
1 Cases Controls p-value
1
Individuals, no. (%) 213 (21.6) 772 (78.4) 78 (22.9) 263 (77.1)
Sex (%) Male 51.2 47.4 43.6 47.9
Female 48.8 52.6 0.3305 56.4 52.1 0.5015
Age, mean (SD) 67.6 (9.8) 59.0 (10.2) ,0.0001 68.3 (10.2) 58.8 (9.6) ,0.0001
Control Nodule Status, no. (%) Benign nodule n/a 420 (54.4) n/a 145 (55.1)
No nodule n/a 222 (28.8) n/a 75 (28.5)
Unknown n/a 130 (16.8) n/a 43 (16.4)
Smoking Status, no. Current 54 421 ,0.0001 25 150 ,0.0001
Ex 85 310 ,0.0001 31 108 ,0.0001
Never 11 6 ,0.0001 7 3 ,0.0001
Unknown 63 35 ,0.0001 15 2 ,0.0001
Smoking (PKY), mean (SD)
{ 47.1 (33.7) 42.3 (24.2) 0.0258 40.9 (30.8) 42.3 (24.6) 0.7003
1For continuous data the differences were tested using t-tests. For categorical data significant differences were tested using the Pearson Chi-Squared Test for
independence.
{Pack-years: product of the self reported number of packs of cigarettes smoked per day and the number of years of smoking.
doi:10.1371/journal.pone.0015003.t002
Table 3. Clinical characteristics of NSCLC cases in the training
and verification sets.
Training
Cases,
n=213,
no. (%)
Verification
Cases,
n=78, no. (%)
Stage NSCLC
1 I 9 9( 4 6 . 5 ) 3 8( 4 9 )
II 32 (15.0) 11 (14)
III 82 (38.5) 27 (35)
Not reported - 2 (2)
Histology Adenocarcinoma 120 (56.3) 49 (62.8)
Squamous 71 (33.3) 18 (23.1)
Large cell 2 (1.0) 2 (2.6)
NSCLC NOS 20 (9.4) 9 (11.5)
1Clinical staging for 17 Stage I, 5 Stage II and 29 Stage III cases, NOS not
otherwise specified.
doi:10.1371/journal.pone.0015003.t003
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as highly specific protein binding reagents in a unique multiplexed
assay that transforms the quantity of each targeted protein into a
corresponding quantity of aptamer, which is quantified with a
custom hybridization array. Protein quantities are recorded as
relative fluorescent units (RFU), which can be converted to
concentrations with standard curves. The platform is highly
automated [26] and scalable to accommodate a broad range of
sample throughput. In this study, 813 protein targets were
measured in 15 mL of serum for each subject, and all 1,326 sera
were analyzed in a continuous process over a period of eight days.
Overall, the results are analogous to a little more than 1,000,000
high quality ELISA measurements. Samples were processed in
multiple 96-well microtiter plates, and all 1,326 samples were
distributed randomly and their identities were completely blinded
throughout the proteomic analysis process.
Biomarker Selection
Biomarkers were selected with a strategy designed to identify
analytes with the highest performance in classifying NSCLC cases
from controls across all study sites and that were least affected by
preanalytical variables. In the first step of this analysis, we
eliminated analytes that exhibited unexpected variation compared
to internal controls, due to, for example, sample instability. In this
process, we chose a set of analytes that performed well in a total of
six naı ¨ve Bayes (NB) classifier training analyses. First we divided
the training set into two distinct populations to control for possible
biological variability between them: (1) all cases and controls with
benign nodules identified by CT; and (2) all cases and all other
smoker controls (nodule status unknown). For each population, we
compared cases to controls in three NB training analyses designed
to control for potential preanalytical variability between study
sites. The three NB analyses started with a unique set of potential
biomarkers based on the following criteria: (1) cases versus controls
KS$0.3 for all comparisons within each of the four study sites; (2)
cases versus controls KS$0.3 for comparing all sites combined; (3)
both criteria one and two were met. For each analysis, we used a
greedy forward search algorithm to select subsets of potential
biomarkers, build NB classifiers (see below), and scored their
performance for classifying lung cancer and controls using the
training set. In this process, this meta-heuristic approach efficiently
searches classifier space to identify potential biomarkers that
perform best in classification. We used a simple measure of
diagnostic performance of classifiers, the numerical sum of
sensitivity + specificity, and measured the frequency with which
potential biomarkers were selected by the greedy algorithm for
inclusion in classifier panels with sensitivity + specificity $1.7. This
step produced a set of potential biomarkers for each of the six
parallel analyses. We selected the final set of biomarkers as the
union of these six sets.
Statistical Methods
The KS statistic is a non-parametric measure of the difference
between two distributions. The two-sample KS Statistic is:
K~supxFa x ðÞ {Fb x ðÞ jj , where Fa x ðÞ and Fb x ðÞ are empirical
cumulative distributions for two populations of values.
The naı ¨ve Bayes classifier assumes independence between the
samples, and models the distributions of the training classes to
make predictions [27]. We used normal distributions to model our
data. However, the features in our data often contain distributions
with heavy tails so maximum likelihood estimation of the
distribution parameters performs poorly. Therefore, we modeled
our distributions as log-normal distributions and used the Gauss-
Newton algorithm to fit the data.
We constructed Bayesian classifiers using sets of potential
biomarkers identified as described above. We used a parametric
model to capture the underlying protein distribution for a given
state. The simplest parametric model for the probability density
function (pdf) for a single protein is a normal distribution,
completely described by a mean u and variance s
2 (Eq. 1).
pdf x ðÞ ~
1
ﬃﬃﬃﬃﬃﬃ
2p
p
s
exp {
1
2
x{m
s
   2   
ð1Þ
Many protein distributions were observed as normal with respect
to the logarithm of the concentration. The numeric cdfs can be fit
to a normal distribution in log concentrations x (Eq. 2).
cdf x ðÞ ~
ð x
{?
pdf y ðÞ dy ð2Þ
The models fit the data well. More complex models of the
probability distribution functions may be used when warranted but
the simple model provided a good description of our data.
To combine multiple markers, we used a multivariate normal
distribution to model the probability density function (pdf) for each
class. For n markers, the multivariate pdf is given by the following
equation (Eq. 3).
pdf x ðÞ ~
1
2p ðÞ
n
2 S jj
1
2
exp {
1
2
x{m ðÞ
tS{1 x{m ðÞ
  
ð3Þ
where x is an n-component vector of protein levels, m is an n-
component vector of mean protein levels, S is the n x n covariance
matrix and |S| and S
21 are its determinant and inverse. In its
simplest form, we can assume a diagonal representation for S.
Such an approximation leads to a naı ¨ve Bayes model, which
assumes independence between the markers. In this work, we
exclusively use the naı ¨ve Bayes model for constructing classifiers.
The parameter values for m and S used in the naı ¨ve Bayes
classification were obtained from nonlinear regression analysis as
described above.
The addition of subsequent markers with good KS distances
will, in general, improve the classification performance if the
subsequently added markers are independent of the first marker.
We searched for optimal marker panels with a ‘‘greedy’’
algorithm, which is any algorithm that follows the problem solving
meta-heuristic of making the locally optimal choice at each stage
with the hope of finding the global optimum. We used the
sensitivity (fraction of true positives) plus specificity (fraction of true
negatives) as a classifier score. The algorithm approach used here
is described as follows. All single analyte classifiers were generated
from a table of potential biomarkers and added to a list. Next, all
possible additions of a second analyte to each of the stored single
analyte classifiers were performed, saving a predetermined
number (10,000 in this case) of the best scoring pairs on a new
list. All possible three marker classifiers are explored using this new
list of the best two-marker classifiers, again saving the best
thousand of these. This process continues until the score either
plateaus or begins to deteriorate as additional markers are added.
Aptamer Proteomics for Early Lung Cancer Detection
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We analyzed 1,326 serum samples from four independent
biorepositories: New York University (NYU) [24]; Roswell Park
Cancer Institute (RPCI) [25]; The University of Pittsburgh (PITT)
[5]; and a commercial biorepository (BioServe (BS)) (Table 1). The
study included patients diagnosed with pathologic or clinical stage I-
III NSCLC and a high-risk control population with a history of long-
term tobacco use, including active and ex-smokers with $10 pack-
years of cigarette smoking (Table 2 and 3). The control populations
were selected randomly within each study to represent the patient
population at risk for lung cancer that would be candidates for CT
screening, with a ratio of case to control of 1 to 3.5.
Samples were randomly distributed into segregated sets for
classifier training and verification (Figure 1) with no significant
differences in demographics between these sets (Table 2). More
than 45% of NSCLC cases were pathologically confirmed stage IA
or IB or clinical stage I with adenocarcinoma representing the
major histological diagnosis (Table 3). All lung cancer patients had
a biopsy-proven cancer diagnosis.
We measured the quantity of 813 proteins in each of the 1,326
samples with our proteomic discovery platform [18]. We followed
a pre-specified two-phase analysis plan to identify biomarkers and
develop a classifier to distinguish lung cancer subjects from
controls within the training set (training phase) and to verify the
classifier performance with the blinded independent verification
set (verification phase). The training phase entailed two steps –
biomarker selection and algorithm training with cross-validation.
To select biomarkers we performed a systematic analysis that
narrowed the potential biomarker field for algorithm training to
increase the probability of true discovery, yet still cast a relatively
broad net. We used a naı ¨ve Bayes (NB) method to systematically
assess potential biomarker performance with pre-specified criteria.
We applied the NB method to subsets of the training data to
broaden our cast for potential biomarkers (see Methods). The
results identified a set of 44 potential biomarkers (Table 4) that
distinguish lung cancer from controls across a range of
comparisons in the training set while minimizing potential
preanalytical variability – artifacts introduced by variations in
sample collection and storage (see below) [28,29].
To develop a potential diagnostic to distinguish NSCLC from
controls, we trained NB classifiers starting with the 44 potential
biomarkers we identified using a ‘‘greedy’’ forward search
algorithm and ten-fold stratified cross validation, starting with
three biomarkers and adding one more at each step. We assessed
classifier performance with pre-specified performance criteria
(Table 5). We constructed 45 seven to twelve-biomarker classifiers
from this set of 44 potential biomarkers that met our performance
criteria, which suggests that there is significant redundancy in the
information contained within the set of potential biomarkers.
Cross-validated classifier performance reached a performance
plateau with twelve biomarkers. Following our analysis plan, we
selected from the 45 resulting classifiers one with the highest
overall performance of pre-specified criteria (Table 5), including
discrimination of NSCLC from controls, detection of Stage I
disease, and detection of cancer in chronic obstructive pulmonary
disease (COPD). In the training set, the classifier achieved 91%
sensitivity, 84% specificity, and an area under the curve (AUC) of
0.91 (Figure 2). The results (Table 6) show that sensitivity is
maintained for Stage I NSCLC (90% for training set). The
classifier performed well on samples from all four study sites
(Figure 3).
The twelve biomarkers are shown in Table 7. The estimated
serum concentrations for these markers span 4 logs (10 pM-
Table 4. Potential NSCLC biomarkers
1.
# Protein Name UniProt ID KS q-value NB Freq
1 BCA-1 O43927 0.34 2.51E-17 1
2 BMP-1 P13497 0.35 3.49E-18 10
3 C1s P09871 0.29 3.92E-13 1
4 C9 P02748 0.41 1.33E-24 6
5 Cadherin-1 P12830 0.32 1.47E-15 206
6 Calpain I P07384
P04632
0.4 8.46E-24 72
7 Catalase P04040 0.32 1.21E-15 2
8 CD30 Ligand P32971 0.28 1.22E-12 51
9 CDK5/p35 Q00535
Q15078
0.27 1.34E-11 31
10 CK-MB P12277
P06732
0.33 2.51E-16 19
11 Contactin-5 O94779 0.29 1.67E-13 3
12 Endostatin P39060 0.28 8.48E-13 33
13 ERBB1 P00533 0.46 6.32E-31 136
14 FGF-17 O60258 0.31 6.12E-15 6
15 FYN P06241 0.13 5.19E-04 14
16 HSP 90a P07900 0.51 7.86E-37 85
17 HSP 90b P08238 0.39 1.50E-22 7
18 IGFBP-2 P18065 0.36 1.87E-19 54
19 IL-15 Ra Q13261 0.29 2.62E-13 4
20 IL-17B Q9UHF5 0.28 1.07E-12 1
21 Importin b1 Q14974 0.4 1.31E-23 30
22 Kallikrein 7 P49862 0.31 1.79E-14 43
23 LDH-H 1 P07195 0.3 8.64E-14 3
24 Legumain Q99538 0.28 2.52E-12 1
25 LRIG3 Q6UXM1 0.34 1.13E-17 25
26 Macrophage man-
nose receptor
P22897 0.37 6.21E-21 21
27 MAPK13 O15264 0.34 4.66E-18 1
28 MEK1 Q02750 0.29 2.62E-13 5
29 MetAP2 P50579 0.44 3.40E-28 7
30 Midkine P21741 0.11 1.67E-03 7
31 MIP-4 P55774 0.29 2.69E-13 43
32 MIP-5 Q16663 0.31 1.53E-14 27
33 MMP-7 P09237 0.38 1.67E-21 36
34 NACa Q13765 0.33 7.57E-17 5
35 NAGK Q9UJ70 0.37 1.25E-20 5
36 Pleiotrophin P21246 0.29 5.02E-13 107
37 PRKCI P41743 0.41 3.81E-25 97
38 Renin P00797 0.25 1.69E-10 2
39 RGM-C Q6ZVN8 0.27 5.43E-12 84
40 SCF sR P10721 0.35 6.97E-19 107
41 sL-Selectin P14151 0.29 7.88E-13 57
42 Ubiquitin+1 P62988 0.33 4.09E-17 1
43 VEGF P15692 0.29 5.47E-13 1
44 YES P07947 0.28 1.73E-12 47
1Measure of the relative importance of potential biomarkers selected with KS
distance (KS), KS FDR-corrected q-value (q-value), frequency for naı ¨ve Bayes
(NB Freq),
doi:10.1371/journal.pone.0015003.t004
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nodules detected by CT (Table 2), and the performance of the
classifier in that subgroup was similar to that of the whole (Table 6).
We also tested the effect of other attributes that could affect
classifier performance such as age, smoking history, and COPD,
but found little effect (Tables 8 and 9). Age has a moderate effect
on the shape of the ROC curve because the probability of cancer
increases with age, but this effect can be controlled by adjusting
the prior probability of cancer in the Bayes classifier model. The
classification performance of the fixed algorithm was tested on the
blinded independent verification set and verified by a third party
reader to achieve 89% sensitivity and 83% specificity, nearly
matching the training set performance.
To determine whether our classification results were affected
either by age, smoking status, or smoking history, which are the
demographics with significant differences between the case and
control populations (Table 2), we compared the classifier
performance on subsets of the training set population divided
into groups based on the median value of these attributes. The
results show similar classifier performance for all subsets (Table 8).
To further assess whether our classification results were affected
either by age, smoking status, or smoking history, we tested for
potential correlation of the twelve biomarkers with these variables.
The results showed no correlations except for endostatin, which
showed a moderate correlation, increasing with age. This effect
can be compensated for by adjusting the prior probability of
cancer in the Bayes classifier model. We also assessed the
specificity of the classifier for the discrimination of controls known
to have airflow obstruction (measured by GOLD score). The
results are shown in Table 9. Spirometry data was incomplete for
NSCLC cases, so we could not calculate sensitivity.
Preanalytical variability underlies common failures to translate
candidate biomarkers into clinically useful tests [20,29]. We
assessed preanalytical variability in this study by measuring
differences in protein levels within the same disease class (NSCLC
or control) between different sites and comparing them to
differences observed between NSCLC and control populations.
The results (Figure 4) show significant preanalytical variability
between sites. However, proteins most affected are distinct from
potential NSCLC biomarkers. Many proteins that exhibit
preanalytical variability (Table 10) are known to be susceptible
to variations in sample collection and handling [28,29]. This result
confirms that pre-analytical variability exists in our study and
provides evidence that, as designed, our study largely overcomes
this variability to maximize the chances of discovering true, robust
biomarkers of NSCLC.
Discussion
The primary findings of this study are 44 potential lung cancer
biomarkers that discriminate stages I-III NSCLC cases from at-
risk heavy smoker controls that can be combined into classifier
panels that meet and exceed pre-specified performance criteria.
The results of this study are novel in the following: (1) most of the
proteins identified in this study have not been identified previously
as serum lung cancer biomarkers; (2) we have identified novel
protein biomarker panels that distinguish lung cancer cases from
appropriate controls with high sensitivity and specificity in an
independent, blinded verification set; and (3) this study achieves a
new level of evidentiary standard in clinical proteomic biomarker
studies as a result of a large sample size, a study design to control
preanalytical variability, and the unique capability of this
proteomic technology to interrogate the circulating proteome
Figure 2. ROC curve for 12-biomarker naı ¨ve Bayes classifier.
doi:10.1371/journal.pone.0015003.g002
Table 5. Criteria for algorithm performance on training and
cross-validation.
Criteria
Minimum
Performance
#
Classifiers
Biomarker frequency in greedy
algorithm classifiers
10 250
Sensitivity (Stage I-III) + Specificity 1.7 94
Stage I Sensitivity 0.85 80
Cross-validation Sensitivity
(Stage I-III)+ Specificity
1.7 50
Cross-validation Stage I Sensitivity 0.85 50
Severe COPD Specificity 0.65 45
doi:10.1371/journal.pone.0015003.t005
Table 6. Performance of Bayesian Classifier to distinguish
NSCLC cases from controls.
Sensitivity
(%), (95% CI)
Specificity
(%), (95% CI)
NSCLC Cases Training Stage I-III 91 (87-95)
Training Stage I 90 (84-96)
10-fold Cross Validation 91 (87-95)
Verification Stage I-III 89 (81-96)
Verification Stage I 87 (78-96)
Controls Training All Controls 84 (81-86)
Training Benign Nodules 82 (78-85)
10-fold Cross Validation 83 (80-86)
Verification All Controls 83 (79-88)
Verification Benign Nodules 85 (79-91)
doi:10.1371/journal.pone.0015003.t006
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unmatched by other broad serum profiling platforms [18],
including mass spectrometry [18], antibody arrays [18], and
autoantibody arrays [18,30–32]. This study is the first large-scale
application of this technology and the largest clinical proteomic
biomarker study to date. As such, this study aims to overcome
critical confounders and limitations of clinical proteomic biomark-
er studies that contribute largely to the lack of translation to the
clinic due to false discovery [20]. These confounders and
limitations include clinical sample integrity, preanalytical variabil-
ity, and inadequate study design and power.
The best overall performing classifier used 12 of the 44
biomarkers and achieved 91% sensitivity and 84% specificity in
cross-validated training and similar performance of 89% sensitivity
and 83% specificity in blinded validation. These results provide
evidence that these biomarkers are valid and that the classifier was
not over-fit to the training data. This performance and the
biological plausibility (following) of the 12 biomarkers are
encouraging for the next phase of development – validation in
an independent clinical study.
The 12 biomarkers identified in this study (Table 4) encompass
functions of cell movement, inflammation, and immune monitor-
ing that may contribute to cancer development. Most of the 12
proteins have been associated generally with cancer biology, some
have been identified as candidate lung cancer biomarkers, none
have been validated as lung cancer biomarkers, and none are used
clinically [33,34]. Four of the 12 proteins have been identified in
serum and lung cancer tissue or cell culture as candidate lung
cancer biomarkers – cadherin-1 [35], endostatin [36], HSP90
[37], and pleiotrophin [38]. Eight of the 12 proteins, CD30 ligand,
LRIG3, MIP-4, PRKCI, RGM-C, SCF-sR, sL-Selectin, and YES,
have not been identified previously in serum as lung cancer
biomarkers and represent novel findings.
Six of the 12 proteins, CD30 ligand, endostatin, HSP90, MIP-4,
pleiotrophin, PRKCI, and YES were observed up-regulated in
Figure 3. ROC curve performance of the 12-biomarker naı ¨ve Bayes NSCLC classifier by study site.
doi:10.1371/journal.pone.0015003.g003
Table 7. Twelve biomarker classifier proteins
1.
Biomarker UniProt ID Direction* Description
Cadherin-1 P12830 down cell adhesion, transcription
regulation
CD30 Ligand P32971 up cytokine
Endostatin P39060 up inhibition of angiogenesis
HSP 90a P07900 up chaperone
LRIG3 Q6UXM1 down protein binding, tumor
suppressor
MIP-4 P55774 up monokine
Pleiotrophin P21246 up growth factor
PRKCI P41743 up serine/threonine protein
kinase, oncogene
RGM-C Q6ZVN8 down iron metabolism
SCF sR P10721 down decoy receptor
sL-Selectin P14151 down cell adhesion
YES P07947 up tyrosine kinase, oncogene
1Up or down regulation in NSCLC cases relative to controls.
doi:10.1371/journal.pone.0015003.t007
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roles in proliferation, invasion, or host inflammatory and immune
response to the tumor. CD30 ligand is a member of the TNF
ligand superfamily, which stimulates T-cell growth. Up-regulation
of this protein correlates with proliferation in hematological
malignancies [36]. Endostatin, best known as an inhibitor of
angiogenesis, has elevated serum levels in several cancers [39].
Overexpression of endostatin and its parent extracellular matrix
protein, collagen XVIII have been associated with poor prognosis
in NSCLC [36].
The chaperone HSP90a is important for the stability of and
function of a wide range of oncoproteins, including BCR-ABL,
ERBB2, EGFR, BRAF, and AKT, among others, and inhibitors
of this protein are now in oncology clinical trials, including
NSCLC [40]. HSP90 may also play a role in tumor cell resistance
to complement mediated cytotoxicity [41]. MIP-4 is over-
expressed in ovarian and gastric cancers, and may have a role in
immunosuppression of the host tumor response [42]. Pleiotrophin
is a growth factor with both mitogenic and angiogenic properties
and levels in the serum of NSCLC patients have been reported to
correlate with disease stage and prognosis [38]. PRKCI is an
oncogene that is often amplified in NSCLC and over-expressed in
lung tumors correlates with poor prognosis [43]. YES, another
protein kinase and member of the src-family of tyrosine kinases,
has a role in malignant transformation and increased protein levels
have been reported in early stages of hepatocarcinoma [44].
We observed decreased levels of proteins in the serum of lung
cancer patients compared to controls, including cadherin-1,
LRIG3, sL-selectin, SCRsR, ERBB1 and RGM-C. Lower
circulating levels of many of these proteins are associated with
relief of inhibition of growth and invasion. For example, cadherin-
1 is critical for cell adhesion and indirectly affects transcriptional
regulation circuits through b-catenin [45]. Consistent with our
results, reduced expression has been reported in lung cancer, and
loss of cadherin-1 is a key event leading to loss of adherence,
tumorgenicity, and metastasis [46]. The LRIG family consists of
membrane proteins with soluble leucine rich repeat domains and
immunoglobulin-like domains. Down-regulation of expression of
this protein in glioblastoma cell lines resulted in increased
proliferation and invasion, decreased apoptosis, and increased
EGFR expression, leading to the hypothesis that LRIG is a tumor
suppressor [47]. L-selectin plays a role in activation of naı ¨ve
lymphocytes that participate in immune surveillance and antitu-
mor immunity. It also mediates the adherence of lymphocytes to
endothelial cells. Lower expression of L-selectin may be a
component of the immune suppression observed in many cancer
patients [48].
Some of the proteins described in this study are the soluble
domains of membrane receptors, and the function of the
circulating form of these proteins may oppose their membrane-
bound counterparts. Turner et al. [49] proposed that soluble SCF-
receptors regulate kit activation. Our results suggest that a low
level of SCF-sR fails to titrate SCF, which makes more SCF
available for binding cancer cells. Unlike the membrane bound
form, soluble RGM-C inhibits hepcidin expression [50,51]. We
find that RGM-C is down regulated in NSCLC serum, consistent
with increased intracellular iron and proliferative cell growth [52].
The limitations of this study include the following. We did not
test cases prior to clinically apparent disease. We did not
demonstrate organ-specificity and many of the markers are known
to be elevated in other cancers. However, the markers will be used
in combination and in the proper diagnostic context, such as with
imaging, smoking history, and symptoms. We did not validate our
findings in an independent set of clinical samples. Our multi-
center study was designed to minimize the effects of potential
preanalytical variability, which is mitigated, but not eliminated by
this study. All of these limitations will be addressed in the next
phase of development, which is enabled by the positive results of
this study.
The biomarkers that we discovered have several potential
clinical applications. The first application is early detection of lung
cancer in long-term smokers when it may be cured by surgery.
Our results are a significant improvement on the performance of
other recently published lung cancer biomarker studies aimed at
early diagnosis [17] using mass spectrometry [24,53,54] or gene
expression [55]. This performance could allow for testing of
individuals with increased lung cancer risk, with subsequent CT
screening based on the blood test result.
A second potential application is a test for diagnosing lung
cancer in subjects with suspicious lung nodules identified by CT,
which could help mitigate the problem of morbidity and cost
associated with surgical interventions. CT screening reveals
suspicious nodules in ,40% of long-term smokers [5,56,57], but
,97% are likely benign [5,57,58]. Protocols for managing these
patients balance the risk of ‘‘watchful waiting’’ with definitive and
Table 8. Performance of classifier in demographic subsets.
Cases Controls
Sensitivity
(%) (95%CI)
Specificity (%)
(95%CI)
Accuracy (%)
(95%CI) AUC
Age #61 57 467 84 (75-94) 89 (86-92) 88 (85-91) 0.91
.61 156 304 93 (89-97) 76 (71-80) 82 (78-85) 0.89
Smoking Status Current 54 421 93 (86-100) 86 (83-90) 87 (84-90) 0.91
Ex 85 310 91 (84-97) 85 (80-89) 86 (82-89) 0.93
Pack Years #40 84 381 91 (84-97) 86 (83-90) 87 (84-90) 0.93
.40 76 347 97 (94-100) 84 (81-88) 87 (84-90) 0.94
doi:10.1371/journal.pone.0015003.t008
Table 9. Classifier specificity by level of airflow obstruction.
Airflow
Obstruction
1
FEV1 %
Predicted
Number of
Patients
Specificity (%),
(95% CI)
GOLD 0/I .80% 411 89 (86-92)
GOLD II 50–80% 167 84 (78-89)
GOLD III/IV ,50% 32 72 (56-87)
1Spirometric classification of airflow obstruction based on GOLD staging [60].
doi:10.1371/journal.pone.0015003.t009
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growth by periodic follow-up CTs, but may miss the opportunity
for early surgical cure. Invasive procedures incur the risk of
complications and death that arise from biopsy or futile
thoracotomy for benign lesions. This risk might be reduced by a
new strategy to assess nodule volume doubling time by CT [13].
However, CT radiation itself increases cancer risk [59].
Based on the discoveries reported here, we have initiated
clinical validation studies of populations at risk for lung cancer.
Our goal is to develop a clinical blood test to enable an earlier
diagnosis. This study is the first to be published in a sequence of
successful biomarker discovery studies that we have already
completed in different cancers and demonstrates the power of
our proteomic technology to discover robust biomarkers in
important diseases. This general approach can also be applied to
discover biomarkers for many more conditions including infec-
tious, inherited, neurological, and metabolic diseases.
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